Last reviewed · How we verify

NCT05359965

Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF

Terminated NA Last updated 9 March 2026
What this trial tests

NA trial testing Positive Airway Pressure in Idiopathic Pulmonary Fibrosis in 7 participants. Terminated before completion.

Timeline
1 October 2019
Primary endpoint
26 March 2024
11 February 2025

Quick facts

Lead sponsorUniversity of Arizona
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment7
Start date1 October 2019
Primary completion26 March 2024
Estimated completion11 February 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Arizona

Who can join

50 and older, any sex, with Idiopathic Pulmonary Fibrosis or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the effect of CPAP therapy on esophageal pH and lung inflammation in patients with idiopathic pulmonary fibrosis (IPF) and sleep apnea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Positive Airway Pressure

Trials testing the same drug.

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

Other University of Arizona trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05359965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing